Management of hepatitis B virus co-infection on and off antiretroviral therapy

Current HIV/AIDS Reports

Volumn 5, Issue 2, 2008, Pages 86-93

  Soriano, Vincent ^a   Vispo, Eugenia ^b   Bottecchia, Marcelle ^b   Sheldon, Julie ^b   Tuma, Paula ^b   Garcia Samaniego, Javier ^b   Barreiro, Pablo ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG SUBSTITUTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MONOTHERAPY; REVIEW; SCREENING TEST; TREATMENT DURATION;

EID: 43249104139     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0014-4     Document Type: Review

References (71)

1. 1. M. Alter 2006 Epidemiology of viral hepatitis and HIV co-infection J Hepatol 44 6 9 10.1016/j.jhep.2005.11.004 Alter M: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44: 6–9.
2. 2. Soriano V, Puoti M, Peters M, et al.: Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-HBV International Panel. AIDS 2008 (in press).
3. 3. C. Thio E. Seaberg R. Skolasky 2002 HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) Lancet 360 1921 1926 12493258 10.1016/S0140-6736(02)11913-1 Thio C, Seaberg E, Skolasky R, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002, 360: 1921–1926.
4. 4. D. Konopnicki A. Mocroft S. Wit de 2005 Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort AIDS 19 2117 2125 10.1097/01.aids.0000163936.99401.fe Konopnicki D, Mocroft A, de Wit S, et al.: Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS 2005, 19: 2117–2125.
5. 5. G. Matthews 2007 The management of HIV and hepatitis B coinfection Curr Opin Infect Dis 20 16 21 17197877 10.1097/QCO.0b013e328012c5aa Matthews G: The management of HIV and hepatitis B coinfection. Curr Opin Infect Dis 2007, 20: 16–21.
6. 6. M. Núñez V. Soriano 2005 Management of patients co-infected with hepatitis B virus and HIV Lancet Infect Dis 5 374 382 15919623 10.1016/S1473-3099(05)70141-9 Núñez M, Soriano V: Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005, 5: 374–382.
7. 7. S. Schaefer 2007 Hepatitis B virus taxonomy and hepatitis B virus genotypes World J Gastroenterol 13 14 21 17206751 1:CAS:528:DC%2BD2sXitFSgtrk%3D Schaefer S: Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007, 13: 14–21.
8. 8. J. Kao 2002 Hepatitis B viral genotypes: clinical relevance and molecular characteristics J Gastroenterol Hepatol 17 643 650 12100608 10.1046/j.1440-1746.2002.02737.x 1:CAS:528:DC%2BD38XntVKiu70%3D Kao J: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002, 17: 643–650.
9. 9. S. Gunther 2006 Genetic variation in HBV infection: genotypes and mutants J Clin Virol 36 3 11 10.1016/S1386-6532(06)80002-8 Gunther S: Genetic variation in HBV infection: genotypes and mutants. J Clin Virol 2006, 36: 3–11.
10. 10. V. Soriano M. Puoti M. Bonacini 2005 Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel AIDS 19 221 240 15718833 10.1097/01.aids.0000163948.62176.e7 Soriano V, Puoti M, Bonacini M, et al.: Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 2005, 19: 221–240.
11. 11. M. Puoti C. Torti R. Bruno 2006 Natural history of chronic hepatitis B in co-infected patients J Hepatol 44 65 70 10.1016/j.jhep.2005.11.015 Puoti M, Torti C, Bruno R, et al.: Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006, 44: 65–70.
12. 12. A. Alberti N. Clumeck S. Collins 2005 Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients J Hepatol 42 615 624 15916745 10.1016/j.jhep.2005.03.003 Alberti A, Clumeck N, Collins S, et al.: Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42: 615–624.
13. 13. V. Levy R. Grant 2006 Antiretroviral therapy for hepatitis B virus-HIV co-infected patients: promises and pitfalls Clin Infect Dis 43 904 910 16941375 10.1086/507532 1:CAS:528:DC%2BD28XhtVKhsrnL Levy V, Grant R: Antiretroviral therapy for hepatitis B virus-HIV co-infected patients: promises and pitfalls. Clin Infect Dis 2006, 43: 904–910.
14. 14. M. Núñez M. Puoti N. Camino 2003 Treatment of chronic hepatitis B in HIV-infected patients: present and future Clin Infect Dis 37 1678 1685 14689351 10.1086/379774 Núñez M, Puoti M, Camino N, et al.: Treatment of chronic hepatitis B in HIV-infected patients: present and future. Clin Infect Dis 2003, 37: 1678–1685.
15. 15. V. Soriano P. Barreiro M. Nuñez 2006 Management of chronic hepatitis B and C in HIV-infected patients J Antimicrob Chemother 57 815 818 16556638 10.1093/jac/dkl068 1:CAS:528:DC%2BD28XjtlamsLc%3D Soriano V, Barreiro P, Nuñez M: Management of chronic hepatitis B and C in HIV-infected patients. J Antimicrob Chemother 2006, 57: 815–818.
16. 16. A. Lok B. McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 17256718 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D [Published erratum appears in Hepatology 2007, 45:1347.] Lok A, McMahon B: Chronic hepatitis B. Hepatology 2007, 45: 507–539. [Published erratum appears in Hepatology 2007, 45:1347.]
17. 17. E. Keeffe D. Dieterich S.-H. Han 2006 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol 24 1003 1016 Keeffe E, Dieterich D, Han S-H, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 24: 1003–1016.
18. 18. J. Hoofnagle E. Doo J. Liang 2007 Management of hepatitis B: Summary of a clinical research workshop Hepatology 45 1056 1075 17393513 10.1002/hep.21627 1:CAS:528:DC%2BD2sXltlWitb0%3D Hoofnagle J, Doo E, Liang J, et al.: Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007, 45: 1056–1075.
19. 19. C. Chen H. Yang J. Su 2006 Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D Chen C, Yang H, Su J, et al.: Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295: 65–73.
20. 20. U. Iloeje H. Yang J. Su 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load Gastroenterology 130 678 686 16530509 10.1053/j.gastro.2005.11.016 Iloeje U, Yang H, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load. Gastroenterology 2006, 130: 678–686.
21. 21. U. Iloeje H. Yang C. Jen 2007 Risk and predictors of mortality associated with chronic hepatitis B infection Clin Gastroenterol Hepatol 5 921 931 17678844 10.1016/j.cgh.2007.06.015 Iloeje U, Yang H, Jen C, et al.: Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5: 921–931.
22. 22. R. Perrillo E. Schiff G. Davis 1990 A randomized, controlled trial of interferon alfa 2-b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 323 295 301 2195346 1:STN:280:DyaK3czgvF2huw%3D%3D Perrillo R, Schiff E, Davis G, et al.: A randomized, controlled trial of interferon alfa 2-b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990, 323: 295–301.
23. 23. V. Martino Di T. Thevenot J. Colin 2002 Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B Gastroenterology 123 1812 1822 12454838 10.1053/gast.2002.37061 Di Martino V, Thevenot T, Colin J, et al.: Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002, 123: 1812–1822.
24. 24. W. Cooksley 2004 Treatment with interferons (including pegylated interferons) in patients with chronic hepatitis B Semin Liver Dis 24 45 53 15192801 10.1055/s-2004-828678 1:CAS:528:DC%2BD2cXlvVensbo%3D Cooksley W: Treatment with interferons (including pegylated interferons) in patients with chronic hepatitis B. Semin Liver Dis 2004, 24: 45–53.
25. 25. P. Marcellin G. Lau F. Bonino 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 15371578 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D Marcellin P, Lau G, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351: 1206–1217.
26. 26. G. Lau T. Piratvisuth K. Luo 2005 Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2965 15987917 10.1056/NEJMoa043470 1:CAS:528:DC%2BD2MXls1SktL8%3D Lau G, Piratvisuth T, Luo K, et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352: 2682–2965.
27. 27. F. Suzuki A. Tsubota Y. Arase 2003 Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan Intervirology 46 182 189 12867757 10.1159/000071460 1:CAS:528:DC%2BD3sXntFyqsbg%3D Suzuki F, Tsubota A, Arase Y, et al.: Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003, 46: 182–189.
28. 28. G. Matthews A. Bartholomeusz S. Locarnini 2006 Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy AIDS 20 863 870 16549970 10.1097/01.aids.0000218550.85081.59 1:CAS:528:DC%2BD28Xis1Sisr8%3D Matthews G, Bartholomeusz A, Locarnini S, et al.: Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20: 863–870.
29. 29. B. Ramos M. Nuñez L. Martin-Carbonero 2007 Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients J Acquir Immune Defic Syndr 44 557 561 17224847 10.1097/QAI.0b013e3180314b46 Ramos B, Nuñez M, Martin-Carbonero L, et al.: Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007, 44: 557–561.
30. 30. P. Marcellin T. Chang S. Lim 2003 Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 808 816 12606735 10.1056/NEJMoa020681 1:CAS:528:DC%2BD3sXhsFKisrc%3D Marcellin P, Chang T, Lim S, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348: 808–816.
31. 31. S. Hadziyannis N. Tassopoulos E. Heathcote 2005 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2673 2681 15987916 10.1056/NEJMoa042957 1:CAS:528:DC%2BD2MXls1Sksbc%3D Hadziyannis S, Tassopoulos N, Heathcote E, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352: 2673–2681.
32. 32. H. Tillmann 2007 Antiviral therapy and resistance with hepatitis B virus infection World J Gastroenterol 13 125 140 17206760 1:CAS:528:DC%2BD2sXitFSgtL0%3D Tillmann H: Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007, 13: 125–140.
33. 33. Y. Benhamou 2006 Treatment algorithm for chronic hepatitis B in HIV-infected patients J Hepatol 44 90 94 10.1016/j.jhep.2005.11.019 1:CAS:528:DC%2BD28Xktl2rug%3D%3D Benhamou Y: Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006, 44: 90–94.
34. 34. J. Sheldon A. Corral B. Rodes 2005 Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir AIDS 19 2036 2038 16260913 10.1097/01.aids.0000189563.79976.05 1:CAS:528:DC%2BD2MXhtFKmsbzM Sheldon J, Corral A, Rodes B, et al.: Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005, 19: 2036–2038.
35. 35. O. Schildgen C. Schewe M. Vogel 2004 Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment AIDS 18 2325 2327 15577546 10.1097/00002030-200411190-00014 Schildgen O, Schewe C, Vogel M, et al.: Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004, 18: 2325–2327.
36. 36. T. Chang C. Lai 2006 Hepatitis B virus with primary resistance to adefovir N Engl J Med 355 322 323 16855278 10.1056/NEJMc066267 1:CAS:528:DC%2BD28XmvF2ru7Y%3D Chang T, Lai C: Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 355: 322–323.
37. 37. O. Schildgen H. Sirma A. Funk 2006 Variant of hepatitis B virus with primary resistance to adefovir N Engl J Med 354 1807 1812 16641397 10.1056/NEJMoa051214 1:CAS:528:DC%2BD28XjvVWgtr0%3D Schildgen O, Sirma H, Funk A, et al.: Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354: 1807–1812.
38. 38. E. Karatayli S. Karayalcin H. Karaaslan 2007 A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment Antivir Ther 12 761 768 17713159 1:CAS:528:DC%2BD2sXpslOlsLw%3D Karatayli E, Karayalcin S, Karaaslan H, et al.: A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12: 761–768.
39. 39. C. Thio S. Locarnini 2007 Treatment of HIV-HBV co-infection: clinical and virological issues AIDS Rev 9 40 53 17474312 Thio C, Locarnini S: Treatment of HIV-HBV co-infection: clinical and virological issues. AIDS Rev 2007, 9: 40–53.
40. 40. M. Seifer R. Hamatake R. Colonno 1998 In vitro inhibition of hepadnavirus polymerase by triphosphates of BMS-200475 and lobucavir Antimicrob Agents Chemother 42 3200 3208 9835515 1:STN:280:DyaK1M%2FlsVyltA%3D%3D Seifer M, Hamatake R, Colonno R, et al.: In vitro inhibition of hepadnavirus polymerase by triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998, 42: 3200–3208.
41. 41. T. Chang R. Gish R. Man De 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 16525137 10.1056/NEJMoa051285 1:CAS:528:DC%2BD28XitFWms7Y%3D Chang T, Gish R, De Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354: 1001–1010.
42. 42. C. Lai D. Shouval A. Lok 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 1011 1020 16525138 10.1056/NEJMoa051287 1:CAS:528:DC%2BD28XitFWlsrY%3D Lai C, Shouval D, Lok A, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354: 1011–1020.
43. 43. D. Tenney S. Levine R. Rose 2004 Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 3498 3507 15328117 10.1128/AAC.48.9.3498-3507.2004 1:CAS:528:DC%2BD2cXnsVehsL0%3D Tenney D, Levine S, Rose R, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48: 3498–3507.
44. 44. S. Innaimo M. Seifer G. Bisacchi 1997 Identification of BMS-200475 as a potent and selective inhibitor of HBV Antimicrob Agents Chemother 41 1444 1448 9210663 1:CAS:528:DyaK2sXktlyrtbs%3D Innaimo S, Seifer M, Bisacchi G, et al.: Identification of BMS-200475 as a potent and selective inhibitor of HBV. Antimicrob Agents Chemother 1997, 41: 1444–1448.
45. 45. M. McMahon B. Jilek T. Brennan 2007 The HBV drug entecavir—effects on HIV-1 replication and resistance N Engl J Med 356 2614 2621 17582071 10.1056/NEJMoa067710 1:CAS:528:DC%2BD2sXmslKjs7o%3D McMahon M, Jilek B, Brennan T, et al.: The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med 2007, 356: 2614–2621.
46. 46. M. Jain C. Zoellner 2007 Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV AIDS 21 2365 2366 18090296 Jain M, Zoellner C: Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV. AIDS 2007, 21: 2365–2366.
47. 47. V. Soriano J. Sheldon P. García-Gasco 2007 Lack of anti-HIV activity of entecavir in an HIV patients co-infected with hepatitis B and delta viruses AIDS 21 2253 2254 18090058 10.1097/QAD.0b013e3281084e4d Soriano V, Sheldon J, García-Gasco P, et al.: Lack of anti-HIV activity of entecavir in an HIV patients co-infected with hepatitis B and delta viruses. AIDS 2007, 21: 2253–2254.
48. 48. Soriano V, Vispo E, Labarga P, Barreiro P: A low antiretroviral activity of the anti-hepatitis B drug entecavir may be enough to select for M184V in HIV-1. AIDS 2008, In press.
49. 49. Domaoal R, McMahon M, Thio C, et al.: Pre-steady state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 2008 (in press).
50. 50. F. Bani-Sadr L. Denoeud P. Morand 2007 Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 45 123 125 17460476 Bani-Sadr F, Denoeud L, Morand P, et al.: Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007, 45: 123–125.
51. 51. Vispo E, Barreiro P, Pineda JA, et al.: Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, In press.
52. 52. A. Ruiz-Sancho J. Sheldon V. Soriano 2007 Telbivudine: a new option for the treatment of chronic hepatitis B Expert Opin Biol Ther 7 751 761 17477811 10.1517/14712598.7.5.751 1:CAS:528:DC%2BD2sXkvVCisb0%3D Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 2007, 7: 751–761.
53. 53. C. Lai N. Leung E. Teo 2005 A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 129 528 536 16083710 1:CAS:528:DC%2BD2MXpvVWmsLs%3D Lai C, Leung N, Teo E, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129: 528–536.
54. 54. S. Lim T. Ng N. Kung 2006 A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B Arch Inter Med 166 49 56 10.1001/archinte.166.1.49 1:CAS:528:DC%2BD28Xps1Wkug%3D%3D Lim S, Ng T, Kung N, et al.: A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Inter Med 2006, 166: 49–56.
55. 55. M. Núñez M. Pérez-Olmeda B. Díaz 2002 Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine AIDS 16 2352 2354 12441815 10.1097/00002030-200211220-00023 Núñez M, Pérez-Olmeda M, Díaz B, et al.: Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002, 16: 2352–2354.
56. 56. M. Nelson S. Portsmouth J. Stebbing 2003 An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals AIDS 17 F7 F10 12478090 10.1097/00002030-200301030-00002 1:CAS:528:DC%2BD38XpsVSrsrY%3D Nelson M, Portsmouth S, Stebbing J, et al.: An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003, 17: F7–F10.
57. 57. G. Dore D. Cooper A. Pozniak 2004 Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus J Infect Dis 189 1185 1192 15031786 10.1086/380398 1:CAS:528:DC%2BD2cXjsleqs7o%3D Dore G, Cooper D, Pozniak A, et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189: 1185–1192.
58. 58. F. Bommel van T. Wunsche S. Mauss 2004 Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 1421 1425 15565615 10.1002/hep.20464 1:CAS:528:DC%2BD2MXhslagtA%3D%3D van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40: 1421–1425.
59. 59. M. Ristig J. Crippin J. Aberg 2002 Tenofovir disoproxil fumarate for chronic hepatitis B in HIV-coinfected individuals for whom interferon alpha and lamivudine therapy have failed J Infect Dis 186 1844 1847 12447773 10.1086/345770 1:CAS:528:DC%2BD3sXit1Wiuw%3D%3D Ristig M, Crippin J, Aberg J, et al.: Tenofovir disoproxil fumarate for chronic hepatitis B in HIV-coinfected individuals for whom interferon alpha and lamivudine therapy have failed. J Infect Dis 2002, 186: 1844–1847.
60. 60. Y. Benhamou H. Fleury P. Trimoulet 2006 Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients Hepatology 43 548 555 16496322 10.1002/hep.21055 1:CAS:528:DC%2BD28XjtVKqtro%3D Benhamou Y, Fleury H, Trimoulet P, et al.: Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43: 548–555.
61. 61. J. Sheldon N. Camino B. Rodes 2005 Selection of hepatitis B virus polymerase mutations in HIV co-infected patients treated with tenofovir Antivir Ther 10 727 734 16218172 1:CAS:528:DC%2BD2MXhtF2ntbbP Sheldon J, Camino N, Rodes B, et al.: Selection of hepatitis B virus polymerase mutations in HIV co-infected patients treated with tenofovir. Antivir Ther 2005, 10: 727–734.
62. 62. M. Peters J. Andersen P. Lynch 2006 Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 Hepatology 44 1110 1116 17058225 10.1002/hep.21388 1:CAS:528:DC%2BD28Xht1aktL7J Peters M, Andersen J, Lynch P, et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44: 1110–1116.
63. 63. C. Thio M. Sulkowski D. Thomas 2005 Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box Clin Infect Dis 41 1035 1040 16142671 10.1086/496921 1:CAS:528:DC%2BD2MXhtV2msrfL Thio C, Sulkowski M, Thomas D: Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 2005, 41: 1035–1040.
64. 64. US Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed February 11, 2008.
65. 65. M. Osborn A. Lok 2006 Antiviral options for the treatment of chronic hepatitis B J Antimicrob Chemother 57 1030 1034 16595637 10.1093/jac/dkl123 1:CAS:528:DC%2BD28XmsFyktr0%3D Osborn M, Lok A: Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006, 57: 1030–1034.
66. 66. Sheldon V, Soriano V: Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008 (in press).
67. 67. J. Sheldon B. Ramos J. Garcia-Samaniego 2007 Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral therapies with anti-HBV activity J Acquir Immune Defic Syndr 46 279 282 18167643 10.1097/QAI.0b013e318154bd89 Sheldon J, Ramos B, Garcia-Samaniego J, et al.: Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral therapies with anti-HBV activity. J Acquir Immune Defic Syndr 2007, 46: 279–282.
68. 68. M. Pouplana de V. Soriano J. Garcia-Samaniego 1995 More severe course of delta hepatitis in HIV-infected patients Genitourin Med 71 132 133 7744408 de Pouplana M, Soriano V, Garcia-Samaniego J, et al.: More severe course of delta hepatitis in HIV-infected patients. Genitourin Med 1995, 71: 132–133.
69. 69. P. Farci 2003 Delta hepatitis: an update J Hepatol 39 212 219 10.1016/S0168-8278(03)00331-3 1:CAS:528:DC%2BD3sXnt1yju78%3D Farci P: Delta hepatitis: an update. J Hepatol 2003, 39: 212–219.
70. 70. Sheldon J, Ramos B, Toro C, et al.: Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV/HBV/HDV co-infected patients? Antivir Ther 2008 (in press).
71. 71. P. Farci L. Chessa C. Balestrieri 2007 Treatment of chronic hepatitis D J Viral Hepat 14 Suppl 58 63 17958644 10.1111/j.1365-2893.2007.00917.x Farci P, Chessa L, Balestrieri C, et al.: Treatment of chronic hepatitis D. J Viral Hepat 2007, 14 (Suppl):58–63.